About N4admin

This author has not yet filled in any details.
So far N4admin has created 38 blog entries.

Video: SiRNA transfection with Nuvec® and subsequent inhibition of mRNA translation

2023-06-23T11:14:52+01:00June 23rd, 2023|Blog, News, Uncategorised|

Our new animation displays how Nuvec’s® unique spiky structure and large surface area allow it to efficiently load, protect and deliver multiple siRNA to a target cell through endocytosis. Once delivered to the cytoplasm, the siRNA binds to the RNA-inducing silencing complex (RISC) to cut and degrade the specific [...]

Article: Could new-generation silica nanoparticles be the next big thing in siRNA delivery systems for cancer treatment? 

2023-05-10T09:49:58+01:00May 4th, 2023|Article, Blog, News|

In our latest article, we look at how Nuvec® offers an alternative to current drug delivery approaches for small interfering RNA (siRNA). Not only is Nuvec® particularly suited to chemical modification, allowing the addition of target specific ligands to receptors on cancer cells, but it may offer the convenience of [...]

The data – evidence based results

2023-01-04T09:28:27+00:00January 4th, 2023|Blog, News|

As a result of recently completed initial testing in vitro on loaded Nuvec®  with two generic siRNA probes, N4 Pharma has created an infographic outlining the key results and detailing how Nuvec®  works to deliver multiple siRNA into the same cell. With siRNA increasingly being used in the development [...]

Article: Deagglomeration of DNA nanomedicine carriers using controlled ultrasonication

2022-09-06T10:17:33+01:00September 6th, 2022|Blog, News|

Ultrasound sonication is a well-established mechanism for the deagglomeration of particle materials in dispersion. In this recently published paper, the National Physical Laboratory investigates the deagglomeration of Nuvec® silica particles with and without the presence of plasmid via controlled sonication. It evaluated the performance of controlled cavitation using different [...]

Poster Presentation: Nuvec® as a gene therapy platform in oncology

2022-07-14T16:00:23+01:00July 14th, 2022|Blog, News|

In collaboration with Nanomerics Ltd, N4 Pharma has released the results of a recent study assessing the potential of Nuvec® , a non-viral nanoparticle delivery system consisting of poly(ethylenimine) coated silica particles, as a gene therapy delivery platform in cancer treatment. Introducing exogenous genetic material to a cell alters [...]

N4 Pharma in the news

2022-07-01T15:44:08+01:00July 1st, 2022|News|

N4 Pharma highlights the potential of Nuvec® as a gene therapy delivery platform by successfully completing a pre-clinical, in-vivo oncology study. The results reinforce the findings from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous (“i.v”) route of administration using [...]

N4 Pharma Oncology programme initial pilot study

2022-01-05T10:42:54+00:00December 20th, 2021|Blog, News|

N4 Pharma has successfully completed an in vivo confirmatory oncology study which reinforces the results from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous ("i.v") route of administration using a DNA plasmid (pDNA) encoding TNF alpha, to assess the [...]

Article: Next gen drug delivery technologies

2021-10-27T09:00:37+01:00October 27th, 2021|Blog, News|

"The development of smart drug delivery systems will improve drug efficacy, reduce costs, and improve storage, and ultimately lead to better treatments for the patient.” N4 Pharma’s CEO, Nigel Theobald, is featured in this month’s BioPharm International magazine talking about some of the next generation technologies that could be [...]

Investigation of Nuvec particles for effective gene delivery: ELRIG 2021

2021-10-21T11:30:09+01:00October 21st, 2021|Blog, News|

Our partners at Medicines Discovery Catapult gave a presentation on behalf of N4 Pharma at the European Laboratory Research & Innovation Group’s (ELRIG) UK meeting in Liverpool this week. The full poster, titled ‘Investigation of Nuvec® particles for effective gene delivery’, can be viewed by clicking here. We're also [...]

New article: Making good vaccines better

2021-06-03T14:38:11+01:00June 3rd, 2021|Blog, News|

Our CEO, Nigel Theobald, is featured in the June issue of The Medicine Maker reviewing the progress made with #covid19vaccines so far. He also looks at how silica nanoparticles like Nuvec® can help to overcome some of the delivery issues that we’ve seen in the vaccines developed to date. "Now that [...]

Go to Top